Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess
drug metabolism/transporter interaction potential––toward a consensus. Pharm Res
2001;18:1071–1080.
UW database. available at http://www.druginteractioninfo.org.
Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients
receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther
1994;56 (6 Pt 1):601–607.
vonMoltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors
of alprazolam metabolismin vitro: effect of serotonin-reuptake-inhibitor antidepres-
sants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23–31.
vonMoltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo
MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human
liver microsomesin vitro: effects of metabolic inhibitors and clinical confirmation of a
predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370–379.
Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate
and a potent inhibitor of both P-glycoprotein and CYP3Ain vitro. Drug Metab
Dispos 2000;28:895–898.
Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P450 3A4:in
vitrodrug–drug interaction patterns are substrate-dependent. Drug Metab Dispos
2000;28:360–366.
Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St
John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin
Pharmacol Ther 2001;70:317–326.
Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Ethnic differences
and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin
Pharmacol Ther 2001;70:228–236.
Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450
probe substrates commonly used by the pharmaceutical industry to studyin vitro
drug interactions. Drug Metab Dispos 2002;30:1311–1319.
Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ.In vitro
metabolism of trazodone by CYP3A: inhibition by ketoconazole and human
immunodeficiency viral protease inhibitors. Biol Psychiatry 2000;47:655–661.
Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. Scientific perspectives on drug
transporters and their role in drug interactionst. Mol Pharm 2006;3:62–69.
Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH. Assessment of
cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther
2001;70:455–461.
Zhu M, Zhao W, Vazquez N, Mitroka JG. Analysis of low level radioactive metabolites
in biological fluids using high-performance liquid chromatography with microplate
scintillation counting: method validation and application. J Pharm Biomed Anal
2005;39:233–245.
Zhu M, Zhang D, Skills G.Quantification and structural elucidation of low quantities
for radiolabeled metabolites using microplate scintillation counting (MSC)
techniques in conjunction with LC/MS. Chowdhury S.K, editor. Identification and
Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS.
Amsterdam: Elsevier; 2005. p:195–223.
236 REGULATORY CONSIDERATIONS OF DRUG METABOLISM AND DRUG